<!doctype html>
<html>

<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>The ASCO Post Timeline V1</title>
  <!-- style sheets -->
  <link rel="stylesheet" href="css/reset.css">
  <link rel="stylesheet" href="css/tap-timline-styles.css">
  <link rel="stylesheet" href="https://fonts.googleapis.com/icon?family=Material+Icons">
  <!-- Free Font Awesome 6 -->
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.5.1/css/all.min.css">
</head>

<body>


  <!-- demo header - delete for live site : START -->

  <div id="shadow-root"></div>



  <script>
    const shadowContainer = document.getElementById("shadow-root");
    const shadow = shadowContainer.attachShadow({ mode: "open" }); shadow.innerHTML = `
<link rel="stylesheet" href="https://ascopost.com/css/bootstrap.css">
<link rel="stylesheet" href="https://ascopost.com/css/TAP.min.css">

<style>
@import url('https://fonts.googleapis.com/css2?family=Roboto:ital,wght@0,100..900;1,100..900&display=swap');

* {
  font-family: "Roboto", serif;
}

</style>

<div class="scoped-content"><nav class="navbar navbar-fixed-top navbar-bootsnipp animate" role="navigation">
<div class="container"> 
<!-- Brand and toggle get grouped for better mobile display --><div class="navbar-header">
<button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#bs-example-navbar-collapse-1" aria-expanded="false">
<span class="sr-only">Toggle navigation</span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button><a class="navbar-brand" href="/"><img class="logo"  src="https://ascopost.com/media/14006457/tap-wt-logo_2017.svg" width="210px" height="43px" alt="The ASCO Post"></a> </div><!-- Collect the nav links, forms, and other content for toggling -->
<div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1">
<ul class="nav navbar-nav navbar-right">
<li class="hidden"> <a href="#page-top"></a> </li><li class="dropdown"> <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">About <span class="caret"></span></a>
<ul class="dropdown-menu">
<li><a href="/about-the-asco-post/">About The ASCO Post</a></li>
<li><a href="/editorial-board/">Editorial Board</a></li>
<li><a href="/rights-and-permissions/">Rights and Permissions</a></li>
<li><a href="/contact">Contact</a></li>
<li class="page-scroll"> <a href="/Subscribe/default.aspx">Subscribe</a> </li></ul>
</li><li class="dropdown"> <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">News <span class="caret"></span></a>
<ul class="dropdown-menu">
<li><a href="/Departments?D=FDA%20Update">FDA Update</a></li>
<li><a href="/Departments?D=Journal%20Spotlight">Journal Spotlight</a></li>
<li><a href="/Departments?D=Expert’s%20Corner">Expert&apos;s Corner</a></li>
<li><a href="/Departments?D=In%20the%20Clinic">In the Clinic</a></li>
<li role="separator" class="divider"></li>
<li><a href="/Issues/">View By Issue</a></li>
<li role="separator" class="divider"></li>
<li><a href="/Departments/">View All</a></li>
</ul>
</li>
<li class="dropdown"> <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Meetings <span class="caret"></span></a>
<ul class="dropdown-menu">
<li><a href='/Meetings/?m=2025+STS+Annual+Meeting'>2025 STS Annual Meeting</a></li><li><a href='/Meetings/?m=2025+ASCO+GI'>2025 ASCO GI</a></li><li><a href='/Meetings/?m=2024+SABCS'>2024 SABCS</a></li><li><a href='/Meetings/?m=Thematic+Newsreels'>Thematic Newsreels</a></li><li><a href='/Meetings/?m=2024+ASH+Annual+Meeting'>2024 ASH Annual Meeting</a></li>
<li role="separator" class="divider"></li>
<li><a href="/calendar">Calendar</a></li>
<li role="separator" class="divider"></li>
<li><a href="/Meetings/">View All</a></li>
</ul>
</li>
<li class="dropdown"> <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Topics <span class="caret"></span></a>
<ul class="dropdown-menu">
<li><a href="/topics/solid-tumors/breast-cancer-highlights/">Breast Cancer</a></li>
<li><a href="/topics/solid-tumors/lung-cancer-highlights/">Lung Cancer</a></li>
<li><a href="/topics/solid-tumors/prostate-cancer-highlights/">Prostate Cancer</a></li>
<li><a href="/topics/hematologic-malignancies/lymphoma-highlights/">Lymphoma</a></li>
<li><a href="/topics/issues-in-oncology/cardio-oncology/">Cardio-oncology</a></li>
<li role="separator" class="divider"></li>
<li><a href="/topics/">View All</a></li>
</ul>
</li>
<li class="dropdown"> <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-haspopup="true" aria-expanded="false">Videos <span class="caret"></span></a>
<ul class="dropdown-menu">
<li><a href="/newsreels/">Newsreels</a></li>
<li><a href="/video-roundtable/">Video Roundtables</a></li>
</ul>
</li>
<li><a href="/podcasts/" class="dropdown-toggle" role="button" aria-haspopup="true" aria-expanded="false">Podcasts </a></li>
<li class="page-scroll"> <a style="color: #00B3BB;" href="/Subscribe/default.aspx"><strong>Subscribe</strong></a> </li>
<li>
<!-- search box start -->
<form action="/search-results/" method="GET" role="search">
<input class="search" type="text" name="q" placeholder="Search..." required>
<input class="button-search" type="submit" value="&nbsp;">
</form>
<!-- search box end -->
</li>
</ul>		
</div>
</div>
</nav>
</div>
`;
  </script>

  <!-- demo header - delete for live site : END -->
  <div class="scroll-container">
    <!-- HERO : START -->
    <div class="tap-timline-top-margin"></div>
    <section id="top" class="tap-timeline-section tap-timeline-section-bg-video" style="background-image: url('');">
      <!-- no background image for video sections -->

      <div class="tap-timeline-video-overlay">
        <video autoplay="" loop=""
          style="background-image:url('https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F67a53d0ac4c7a934ee91e8b9_AdobeStock_137983601_a-poster-00001.jpg')"
          muted="" playsinline="" data-wf-ignore="true" data-object-fit="cover">
          <source
            src="https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F67a53d0ac4c7a934ee91e8b9_AdobeStock_137983601_a-transcode.mp4"
            data-wf-ignore="true">
          <source
            src="https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F67a53d0ac4c7a934ee91e8b9_AdobeStock_137983601_a-transcode.webm"
            data-wf-ignore="true">
        </video>
      </div>

      <article class="tap-timeline-article-container fade-in-left">
        <h5>Historic Milestones</h5>
        <h1>HER2-Positive Metastatic Breast Cancer</h1>
        <div class="tap-timeline-hero-bar-accent"></div>
        <p>Over the past two decades, advancements in treatment options for HER2-positive metastatic breast cancer have
          transformed the standard of care, leading to significantly improved outcomes, extended time-to-progression,
          and
          enhanced overall survival rates. For more details, view key milestones as reported by The ASCO Post.</p>
        <a href="#item-1" class="tap-timeline-down-arrow-btn"> <i class="material-icons">arrow_downward</i></a>
      </article>
    </section>
    <!-- HERO : END -->


    <div class="tap-timeline-container">
      <main class="tap-timeline-main">

        <!-- ITEM 1 : START -->
        <section id="item-1" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a13e47b0db5692e314fea5_nci-vol-10574-300_Treatment-resistant-breast-cancer-cells.jpg');">

          <article class="tap-timeline-article-container fade-in-left">
            <h5>2017</h5>
            <h2>Second-Line Therapy:</h2>
            <p>Previously, TDM-1 was the standard second-line treatment after taxane and trastuzumab. The
              <strong>EMILIA</strong> trial demonstrated TDM-1's superiority over lapatinib plus capecitabine.
            </p>
            <p class="tap-timeline-author">By Matthew Stenger</p>
            <a target="_blank" href="https://ascopost.com/News/55667" class="tap-timeline-btn">Read More <i
                class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 1 : END -->

        <!-- ITEM 2 : START -->
        <section id="item-2" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a53f9d9163ad1f93243811_AdobeStock_266980135.jpeg');">
          <article class="tap-timeline-article-container fade-in-left">
            <h5>2019</h5>
            <h2>First-line Therapy (2024 Standard of Care):</h2>
            <p>The current standard front-line therapy is a combination of taxane (docetaxel or paclitaxel),
              trastuzumab,
              and pertuzumab, based on the CLEOPATRA trial results.</p>
            <p class="tap-timeline-author">By Caroline Helwick</p>
            <a target="_blank"
              href="https://ascopost.com/issues/july-10-2019/cleopatra-end-of-study-analysis-in-metastatic-breast-cancer/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 2 : END -->

        <!-- ITEM 3 : START -->
        <section id="item-3" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a53ca1a27e6e25307270a3_AdobeStock_838684473.jpg');">
          <article class="tap-timeline-article-container fade-in-left">
            <h5>2020 - 2023</h5>
            <h2>Emerging Therapies:</h2>
            <p><strong>Trastuzumab Deruxtecan (T-DXd):</strong> Shown to have better progression-free survival and
              overall
              survival compared to TDM-1 in the DESTINY-Breast03 study. This therapy might move to frontline settings
              pending DESTINY-Breast09results.</p>
            <p class="tap-timeline-author">By Jo Cavallo</p>
            <a target="_blank"
              href="https://ascopost.com/issues/october-10-2021/destiny-breast03-trial-supports-second-line-use-of-t-dxd-in-metastatic-her2-positive-breast-cancer/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            <hr>
            <p><strong>Tucatinib:</strong> Added to TDM-1 in the <strong>HER2CLIMB-02</strong> study, showed improved
              progression-free survival but did not demonstrate statistically significant overall survival benefits
              early
              on.</p>
            <p class="tap-timeline-author">By Alice Goodman</p>
            <a target="_blank"
              href="https://ascopost.com/issues/december-25-2023/tucatinib-plus-t-dm1-extends-progression-free-survival-vs-t-dm1-alone-in-advanced-her2-positive-breast-cancer/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 3 : END -->

        <!-- ITEM 4 : START -->
        <section id="item-4" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a540657ccb1ad5e5b3e290_AdobeStock_907164824.jpeg');">
          <article class="tap-timeline-article-container fade-in-left">
            <h5>2020 - 2023</h5>
            <h2>Post-TDM-1 Options:</h2>
            <p>T-DXd: Based on DESTINY-Breast02 results, useful after progression on TDM-1</p>
            <p class="tap-timeline-author">By Jo Cavallo</p>
            <a target="_blank"
              href="https://ascopost.com/news/april-2023/trastuzumab-deruxtecan-vs-physician-s-choice-in-her2-positive-metastatic-breast-cancer-previously-treated-with-trastuzumab-emtansine/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
            <hr>
            <p>Tucatinib plus Capecitabine: Effective per the HER2CLIMB study, especially beneficial for patients with
              brain metastases.</p>
            <p class="tap-timeline-author">By Jo Cavallo</p>
            <a target="_blank"
              href="https://ascopost.com/issues/december-25-2023/tucatinib-plus-t-dm1-extends-progression-free-survival-vs-t-dm1-alone-in-advanced-her2-positive-breast-cancer/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 4 : END -->

        <!-- ITEM 5 : START -->
        <section id="item-5" class="tap-timeline-section tap-timeline-section-bg-effect"
          style="background-image: url('images/67a540fe6c017a9c3f344ac6_AdobeStock_933486027.jpeg');">
          <article class="tap-timeline-article-container fade-in-left">
            <h5>2020 - 2023</h5>
            <h2>Brain Metastases</h2>
            <ul>
              <li>Prevalence: Up to 50% of HER2-positive metastatic breast cancer patients develop brain metastases.
              </li>
              <li>Treatment Options: Tucatinib-based regimens are preferred for active brain metastases. T-DXd has shown
                efficacy in stable brain metastases, with ongoing studies exploring its effectiveness in active cases.
              </li>
            </ul>
            <p class="tap-timeline-author">By Matthew Stenger</p>
            <a target="_blank"
              href="https://ascopost.com/issues/digital-supplement-sabcs-meeting-highlights-2023/highlights-from-the-2023-san-antonio-breast-cancer-symposium/"
              class="tap-timeline-btn">Read More <i class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 5 : END -->

        <!-- ITEM 6 : START -->
        <section id="item-6" class="tap-timeline-section tap-timeline-section-bg-video tap-timeline-section-bg-effect"
          style="background-image: url('');">


          <!-- no background image for video sections -->
          <div class="tap-timeline-video-overlay">

            <video class="bg-video" autoplay="" loop=""
              style="background-image:url('https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F678ae1ab10feeb94dd33123e_ASCO%20LOOP%2016s%20under%2030mb-poster-00001.jpg')"
              muted="" playsinline="" data-wf-ignore="true" data-object-fit="cover">
              <source
                src="https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F678ae1ab10feeb94dd33123e_ASCO%20LOOP%2016s%20under%2030mb-transcode.mp4"
                data-wf-ignore="true">
              <source
                src="https://cdn.prod.website-files.com/6772b93964a25d4bb6da8cd3%2F678ae1ab10feeb94dd33123e_ASCO%20LOOP%2016s%20under%2030mb-transcode.webm"
                data-wf-ignore="true">
            </video>
          </div>


          <article class="tap-timeline-article-container fade-in-left">
            <h5>August 2024</h5>
            <h2>Current Practice</h2>
            <p>For first-line therapy, the standard is THP (taxane, trastuzumab, pertuzumab), followed by T-DXd if
              needed.
              For brain metastases, tucatinib-based regimens are recommended. After <strong>T-DXd</strong>, other
              options
              include TDM-1, tucatinib-based regimens, lapatinib, and various chemotherapy or endocrine therapies.
              &ldquo;HER2-positive metastatic breast cancer survival has greatly improved, shifting from the worst
              prognosis to one of the best due to targeted therapies.&rdquo;</p>
            <p class="tap-timeline-author">Sara Hurvitz</p>
            <a target="_blank"
              href="https://ascopost.com/videos/ibc-west-2024/sara-hurvitz-on-new-therapeutic-strategies-for-her2-positive-metastatic-disease-including-brain-metastases/"
              class="tap-timeline-btn">Watch Video <i class="material-icons">arrow_forward</i></a>
          </article>
        </section>

        <!-- ITEM 6 : END -->

      </main>



      <!-- timeline sidebar : START -->
      <aside class="tap-timeline-aside fade-in-right">




        <h5>Historic Milestones</h5>
        <h3><a href="#top">HER2-Positive Metastatic Breast Cancer</a></h3>
        <!-- year 1 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-1" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-1" class="tap-timeline-aside-year">2017</a>
            <a href="#item-1" class="tap-timeline-aside-blurb">
              <p>Second-Line Therapy</p>
            </a>
          </div>
        </section>
        <!-- year 1 : END -->

        <!-- year 2 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-2" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-2" class="tap-timeline-aside-year">2019</a>
            <a href="#item-2" class="tap-timeline-aside-blurb">
              <p>Firts-Line Therapy</p>
            </a>
          </div>
        </section>
        <!-- year 2 : END -->

        <!-- year 3 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-3" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-3" class="tap-timeline-aside-year">2020 – 2023</a>
            <a href="#item-3" class="tap-timeline-aside-blurb">
              <p>Emerging Therapies</p>
            </a> <a href="#item-4" class="tap-timeline-aside-blurb">
              <p>Post-TDM-Options</p>
            </a> <a href="#item-5" class="tap-timeline-aside-blurb">
              <p>Brain Metastases</p>
            </a>
          </div>
        </section>
        <!-- year 3 : END -->

        <!-- year 4 : START -->

        <section class="tap-timeline-aside-section">
          <div class="tap-timeline-dot-line-container"> <a href="#item-6" class="tap-timeline-aside-dot">&nbsp;</a>
            <div class="tap-timeline-aside-line"></div>
          </div>
          <div>
            <a href="#item-6" class="tap-timeline-aside-year">2024</a>
            <a href="#item-6" class="tap-timeline-aside-blurb">
              <p>Current Practive</p>
            </a>
          </div>
        </section>
        <!-- year 4 : END -->

      </aside>
      <!-- timeline sidebar : START -->

      <!-- timeline mobile button -->

      <button class="tap-timeline-aside-mobile-menu"><i class="fa-solid fa-list"></i></button>


    </div>
  </div>



  <!-- timeline animation js -->

  <script src="js/timeline-animation.js"></script>

  <!-- animation fade js -->

  <script src="js/animation-fade.js"></script>

  <!-- mobile timeline menu js -->

  <script src="js/mobile-timeline-menu.js"></script>

</body>

</html>